Aileron Therapeutics, Inc. Aktie

0,75 $

0,59 %

Nasdaq, Fr, 25.09.2026.

ISIN

US00887A1051

Symbol

ALRN

Berichte

Quartal | Jahr

Index

NASDAQ Composite

Sektor

Pharma, Biotechnologie und Life Sciences

Industrie

Biotechnologie

Mit

tracken

Übersicht Analysten Charts Ownership Strategien

Aileron Therapeutics, Inc. Aktienkurs

0,75 $

-20,65 96,50 % 5 J.

Nasdaq, Schlusskurs Fr, 25.09.2026

+0,00 0,59 %

ISIN

US00887A1051

Symbol

ALRN

Berichte

Quartal | Jahr

Index

NASDAQ Composite

Sektor

Pharma, Biotechnologie und Life Sciences

Industrie

Biotechnologie

Als kostenloser aktien.guide Basis-Nutzer kannst Du die Scores zu allen 9.127 weltweiten Aktien einsehen.

Jetzt kostenlos registrieren

Kennzahlen

Basis

Marktkapitalisierung

64,6 Mio. $

Enterprise Value

23,9 Mio. $

Nettoverschuldung

positiv

Cash

40,7 Mio. $

Anzahl Aktien

85,8 Mio.

Bewertung (TTM | erwartet)

KGV

negativ

KUV

- | -

EV/Sales

- | -

EV/FCF

negativ

KBV

1,2

Finanzielle Stabilität

Eigenkapitalquote

70,0 %

Eigenkapitalrendite

-294,8 %

ROCE

-87,9 %

ROIC

Verschuldungsgrad

0,0

Finanzen (TTM | erwartet)

Umsatz

0,0 $ | 0,0 $

EBITDA

-49,5 Mio. $

EBIT

-49,5 Mio. $

Nettogewinn

-49,8 Mio. $

Free Cashflow

-18,8 Mio. $

Wachstum (TTM | erwartet)

Umsatz

- | -

EBITDA

19,4 %

EBIT

19,4 %

Nettogewinn

15,9 %

Free Cashflow

11,3 %

Marge

Brutto

EBITDA

EBIT

Netto

Free Cashflow

Weitere

EPS

-0,7 $

FCF je Aktie

-0,2 $

Short Interest

1,1 %

Mitarbeiter

Umsatz je MA

0,0 $

Aileron Therapeutics, Inc. Aktie Analyse

Scores kostenlos freischalten

??

9 Analysten haben eine Aileron Therapeutics, Inc. Prognose abgegeben:

7x Kaufen

78 %

2x Halten

22 %

Mehr Details zu Analystenschätzungen inkl. Kursziele

9 Analysten haben eine Aileron Therapeutics, Inc. Prognose abgegeben:

Kaufen

78 %

Halten

22 %

Analystenschätzungen inkl. Kursziele

Aileron Therapeutics, Inc. Events

Vergangene Events

JUL

Shareholder/Analyst Call - Rein Therapeutics Inc.

vor 2 Monaten

1. Management Discussion

Operator

Hello, and welcome to the 2026 Annual Meeting of Stockholders of Rein Therapeutics, Inc. Please note that today's meeting is being recorded. [Operator Instructions]

It is now my pleasure to turn today's meeting over to Brian Windsor, President and Chief Executive Officer of Rein Therapeutics Inc., Dr. Windsor, the floor is yours.

Brian Windsor executive

Good morning, and welcome to the 2026 Annual Meeting of Stockholders of Rein Therapeutics, Inc. I am Brian Windsor, President and Chief Executive Officer of Rein, and I will be presiding over this meeting.

At this time, I call the meeting to order. This year, we are holding our annual meeting in an all-virtual format and are pleased to have everyone join this live webcast. We have designed this meeting to provide stockholders the same rights and opportunities to participate as they would at an in-person meeting.

Before we get to the formal business of the meeting, I would like to make some introductions. Joining us at the meeting today are: Josef H. von Rickenbach, our Chairman and Director, Alan A. Musso. Also from our management team, Tim Cunningham, Interim Chief Financial Officer.

I would also like to introduce Sharona Ellevold, a representative from Computershare Trust Company N.A., our transfer agent, and she has been appointed to act as Inspector of Election.

In order to conduct an orderly meeting, I call your attention to the rules of nduct posted on the virtual meeting website, which include information about participating in the meeting, including asking questions.

I have received an affidavit from the company's transfer agent, Computershare Trust Company N.A., certifying that the notice of the annual meeting and proxy statement were sent to all stockholders of record as of May 21, 2026.

Our first order of business at this meeting is to determine whether the shares represented at this meeting, either in person via this virtual meeting or by proxy, are sufficient to constitute a quorum for the purpose of transacting business. Holders of 85,539,032 shares of common stock are entitled to vote at this meeting. The Inspector of Election has informed me that they are present at this meeting, either in person or by proxy a total of 63,703,884 shares of common stock or approximately 74.7% of all shares entitled to vote at this meeting. Therefore, I hereby declare that a quorum exists.

Turning now to the items to be voted on at this meeting, as indicated in the notice of meeting and accompanying documents that were made available to stockholders.

The first matter to be voted on is the election of 2 Class III directors to serve for a term expiring at the 2029 Annual Meeting of Stockholders and until his successor is duly elected and qualified.

The nominees for this election are Josef H. von Rickenbach and Reinhard J. Ambrose Ph.D. The second matter to be voted on is the approval of an increase in the authorized shares. The third matter to be voted on is the approval of CBIZ as the company's independent audit firm. The fourth and final matter to be voted on is the approval, on a nonbinding advisory basis, of our named executive officer compensation.

If there are any questions on the proposals, they may be submitted on the virtual meeting website. If asking a question, please also include your name and affiliation to the company.

Tim, do we have any questions germane to the meeting at this time?

Timothy Cunningham executive

Brian, there are no questions germane to the meeting.

Brian Windsor executive

Thank you. I hereby declare the polls are now open for each matter to be voted upon today. If you have not yet voted or if you have previously voted by proxy and wish to change your vote, you may vote by using the Cast Your Vote link provided on the virtual meeting website and following the instructions there. We will pause briefly to allow stockholders to vote.

[Voting]

Brian Windsor executive

Now that everyone has had an opportunity to vote, the business items on the agenda for this meeting are complete, and the polls are now closed.

Will Sharona Ellevold please tabulate the votes?

We now have the preliminary report of the results of the meeting. Based on this report, the nominees for directors have been elected as Class III directors; the increase in the number of authorized shares has been approved; CBIZ has been appointed as the company's independent audit firm; the compensation of named executive officers on a nonbinding advisory basis has been approved.

The final vote results will be included in the Form 8-K that will be filed within 4 business days after this meeting.

As there is no further business to come before the meeting, I would like to thank each stockholder who sent in a proxy for this meeting, and I especially would like to thank you who are here for virtually attending.

I hereby declare this meeting adjourned.

Operator

The meeting has now concluded. Thank you for joining. You may now disconnect.

Finanzdaten von Aileron Therapeutics, Inc.

Gewinn- und VerlustrechnungGuV Bilanz Cashflow

Quartal TTM Jährlich

Jun '26		+/- %
Umsatz	- -	- 100 %
- Direkte Kosten	- -	- -
Bruttoertrag	- -	- -
- Vertriebs- und Verwaltungskosten	10 10	4 % 4 % -
- Forschungs- und Entwicklungskosten	10 10	28 % 28 % -
EBITDA	-49 -49	19 % 19 % -
- Abschreibungen	- -	- -
EBIT (Operatives Ergebnis) EBIT	-49 -49	19 % 19 % -
Nettogewinn	-50 -50	16 % 16 % -

Angaben in Millionen USD.

Auf Wunsch erhältst Du jeden Morgen pünktlich zum Frühstück eine E-Mail, die alle für Dich relevanten Aktien-News enthält.

News kostenlos abonnieren

Firmenprofil

Aileron Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich mit der Entwicklung und Kommerzialisierung einer neuen Klasse von Therapeutika zur Behandlung von Krebs und anderen Krankheiten beschäftigt. Es konzentriert sich auf seinen Hauptproduktkandidaten ALRN-6924, ein zelldurchdringendes Peptid, das die Interaktion der p53-Suppressoren MDM2 und MDMX mit dem Tumorsuppressor p53 unterbricht, um die Tumorunterdrückung bei nicht-mutierten oder Wildtyp-Krebsarten zu reaktivieren. Das Unternehmen wurde im Juni 2005 von Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III und Loren David Walensky gegründet und hat seinen Hauptsitz in Cambridge, MA.

Hauptsitz	USA
CEO	Dr. Windsor
Mitarbeiter	10
Gegründet	2001
Webseite	www.reintx.com

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Jetzt starten